Cargando…
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
BACKGROUND: The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC). Antiangiogenic therapy causes hypoxic stress within tumor cells, which activates autophagy as a survival mechanism. The histone dea...
Autores principales: | Karasic, Thomas B, Brown, Timothy J, Schneider, Charles, Teitelbaum, Ursina R, Reiss, Kim A, Mitchell, Tara C, Massa, Ryan C, O’Hara, Mark H, DiCicco, Lisa, Garcia-Marcano, Luis, Amaravadi, Ravi K, O’Dwyer, Peter J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438902/ https://www.ncbi.nlm.nih.gov/pubmed/35552447 http://dx.doi.org/10.1093/oncolo/oyac078 |
Ejemplares similares
-
E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018) -
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023) -
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
por: Aggarwal, Charu, et al.
Publicado: (2023) -
Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018) -
A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)